Transarterial chemoembolization (TACE) for unresectable HCC: A new life begins?

European Review for Medical and Pharmacological Sciences

Volumn 14, Issue 4, 2010, Pages 356-362

  Biolato, M ^a   Marrone, G ^a   Racco, S ^a   Di Stasi, C ^b   Miele, L ^a   Gasbarrini, G ^a   Landolfi, R ^a   Grieco, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Istituto di Radiologia di Universita Cattolica del Sacro Cuore di Roma   (Italy)

Author keywords

Chemoembolization; Drug eluting beads; Hepatocellular carcinoma; Liver cancer; Sorafenib

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DOXORUBICIN; GELFOAM; IODINATED POPPYSEED OIL; POLYVINYL ALCOHOL; SORAFENIB;

ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ANGIOGRAPHY; ANTIANGIOGENIC THERAPY; ASCITES; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CYTOPENIA; DRUG DELIVERY SYSTEM; DRUG ELUTING BEAD; DRUG RETENTION; DRUG TUMOR LEVEL; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMAN; ISCHEMIA; JAUNDICE; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; NAUSEA; PATIENT SELECTION; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; REVIEW; SIDE EFFECT; SPLEEN ABSCESS; TUMOR LOCALIZATION;

ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS;

EID: 77953208087     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. PARKIN DM, BRAY F, FERLAY J, PISANI P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74-108.
2. LLOVET JM, BURROUGHS A, BRUIX J. Hepatocellular carcinoma. Lancet 2003 6; 362(9399): 1907-1917.
3. LLOVET JM, FUSTER J, BRUIX J; BARCELONA-CLÍNIC LIVER CANCER GROUP. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10: S115-S120.
4. GRIECO A, POMPILI M, CAMINITI G, MIELE L, COVINO M, ALFEI B, RAPACCINI GL, GASBARRINI G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411-418.
5. CHEN MS, LI JQ, ZHENG Y, GUO RP, LIANG HH, ZHANG YQ, LIN XJ, LAU WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328.
6. ORLANDO A, LEANDRO G, OLIVO M, ANDRIULLI A, COTTONE M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 514-524.
7. CHO YK, KIM JK, KIM MY, RHIM H, HAN JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49: 453-459.
8. ARII S, YAMAOKA Y, FUTAGAWA S, INOUE K, KOBAYASHI K, KOJIRO M, MAKUUCHI M, NAKAMURA Y, OKITA K, YAMADA R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-1229.
9. FARINATI F, SERGIO A, BALDAN A, GIACOMIN A, DI NOLFO MA, DEL POGGIO P, BENVEGNU L, RAPACCINI G, ZOU M, BORZIO F, GIANNINI EG, CATURELLI E, TREVISANI F. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 2009; 9: 33.
10. DOYON D, MOUZON A, JOURDE AM, REGENSBERG C, FRILEUX C. L'embolisation arterielle hepatique dans les tumeurs malignes du foie. Ann Radiol (Paris) 1974; 17: 593-603.
11. MARELLI L, STIGUANO R, TRIANTOS C, SENZOLO M, CHOLONGITAS E, DAVIES N, TIBBALLS J, MEYER T, PATCH DW, BURROUGHS AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
12. Lu W, Li YH, Yu ZJ, He XF, Chen Y, Zhao JB, Zhu ZY. A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. Hepatogastroenterology 2007; 54: 1499-1502. (Pubitemid 47203456)
13. LLOVET JM, BRUIX J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48: S20-S37.
14. LAU WY, LAI EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008; 7: 237-257. (Pubitemid 351895383)
15. BRUIX J, SHERMAN M; PRACTICE GUIDELINES COMMITTEE, AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
16. VERO V, RACCO S, BIOLATO M, POMPILI M, GASBARRINI G, MIELE L, GRIECO A. The treatment of hepatocellular carcinoma: an update. Minerva Med 2009; 100: 173-193.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
18. FORNER A, AYUSO C, VARELA M, RIMOLA J, HESSHEIMER AJ, DE LOPE CR, REIG M, BIANCHI L, LLOVET JM, BRUIX J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115: 616-623.
19. LLOVET JM, BRUIX J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
20. MILLONIG G, GRAZIADEI IW, FREUND MC, JASCHKE W, STADLMANN S, LADURNER R, MARGREITER R, VOGEL W. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279. (Pubitemid 46351654)
21. Lo CM, NGAN H, TSO WK, LIU CL, LAM CM, POON RT, FAN ST, WONG J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
22. LLOVET JM, REAL MI, MONTAÑA X, PLANAS R, COLL S, APONTE J, AYUSO C, SALA M, MUCHART J, SOLÀ R, RODÉS J, BRUIX J; BARCELONA LIVER CANCER GROUP. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359(9319): 1734-1739.
23. CAMMÀ C, SCHEPIS F, ORLANDO A, ALBANESE M, SHAHIED L, TREVISANI F, ANDREONE P, CRAXÌ A, COTTONE M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54.
24. GIANNINI EG, BODINI G, CORBO M, SAVARINO V, RISSO D, DI NOLFO MA, DEL POGGIO P, BENVEGNÙ L, FARINATI F, ZOLI M, BORZIO F, CATURELLI E, CHIARAMONTE M, TREVISANI F; ITALIAN LIVER CANCER (ITA.LI.CA.) GROUP. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31: 493-501.
25. LLOVET JM, DI BISCEGLIE AM, BRUIX J, KRAMER BS, LENCIONI R, ZHU AX, SHERMAN M, SCHWARTZ M, LOTZE M, TALWALKAR J, GORES GJ; PANEL OF EXPERTS IN HCC-DESIGN CLINICAL TRIALS. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
26. GERUNDA GE, NERI D, MERENDA R, BARBAZZA F, ZANGRANDI F, MEDURI F, BISELLO M, VALMASONI M, GANGEMI A, FACCIOLI AM. Role of transarterial chemoembolization before liver resection for hepatocarcinoma. Liver Transpl 2000; 6: 619-626.
27. Koda M, Murawaki Y, Mitsuda A, Oyama K, Okamoto K, Idobe Y, Suou T, Kawasaki H. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 2001; 92: 1516-1524. (Pubitemid 32947837)
28. KAMADA K, KITAMOTO M, AIKATA H, KAWAKAMI Y, KONO H, IMAMURA M, NAKANISHI T, CHAYAMA K. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am J Surg 2002; 184: 284-290.
29. SHIBATA T, ISODA H, HIROKAWA Y, ARIZONO S, SHIMADA K, TOGASHI K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 2009; 252: 905-913.
30. CHENG BQ, JIA CQ, LIU CT, FAN W, WANG QL ZHANG ZL, YI CH. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA 2008; 299: 1669-1677.
31. ALOIA TA, ADAM R, SAMUEL D, AZOULAY D, CASTAING D. A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. J Gastrointest Surg 2007; 11: 1328-1332.
32. OTTO G, HERBER S, HEISE M, LOHSE AW, MÖNCH C, BITTINGER F, HOPPE-LOTICHIUS M, SCHUCHMANN M, VICTOR A, PITTON M. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267.
33. LEWIS AL, GONZALEZ MV, LLOYD AW, HALL B, TANG Y, WILLIS SL, LEPPARD SW, WOLFENDEN LC, PALMER RR, STRATFORD PW. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17(2 Pt 1): 335-342.
34. VARELA M, REAL MI, BURREL M, FORNER A, SALA M, BRUNET M, AYUSO C, CASTELLS L, MONTAÑÅ X, LLOVET JM, BRUIX J. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481.
35. MALAGARI K, CHATZIMICHAEL K, ALEXOPOULOU E, KELEKIS A, HALL B, DOURAKIS S, DELIS S, GOULIAMOS A, KELEKIS D. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008; 31: 269-280.
36. LAMMER J, MALAGARI K, VOGL T, PILLEUL F, DENYS A, WATKINSON A, PITTON M, SERGENT G, PFAMMATTER T, TERRAZ S, BENHAMOU Y, AVAJON Y, GRUENBERGER T, POMONI M, LANGENBERGER H, SCHUCHMANN M, DUMORTIER J, MUELLER C, CHEVALUER R LENCIONI R; PRECISION V INVESTIGATORS. Prospective randomized study of doxorubicin-eluting- bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
37. MALAGARI K, POMONI M, KELEKIS A, POMONI A, DOURAKIS S, SPYRIDOPOULOS T, MOSCHOURIS H, EMMANOUIL E, RIZOS S, KELEKIS D. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with beadblock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2009 Nov 24. [Epub ahead of print]
38. SERGIO A, CRISTOFORI C, CARDIN R, PIVETTA G, RAGAZZI R, BALDAN A GIRARDI L, CILLO U, BURRA P, GIACOMIN A, FARINATI F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-921.
39. LLOVET JM, RICCI S, MAZZAFERRO V, HILGARD P, GANE E, BLANC JF, DE OLIVEIRA AC, SANTORO A RAOUL JL FORNER A, SCHWARTZ M, PORTA C, ZEUZEM S, BOLONDI L, GRETEN TF, GALLE PR, SEITZ JF, BORBATH I, HÄUSSINGER D, GIANNARIS T, SHAN M, MOSCOVICI M, VOLIOTIS D, BRUIX J; SHARP INVESTIGATORS STUDY GROUP. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
40. STREBEL BM, DUFOUR JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008; 8: 1743-1749.
41. HOFFMANN K, GUMM H, RADELEFF B, RICHTER G, HEINING C, SCHENKEL I, ZAHLTEN-HINGURANAGE A SCHIRRMACHER P, SCHMIDT J, BÜCHLER MW, JAEGER D, VON KALLE C, SCHEMMER P. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa. BMC Cancer 2008; 8: 349.